Published in final edited form as:

Pediatr Blood Cancer. 2014 February ; 61(2): 373–375. doi:10.1002/pbc.24741.

Hypersensitivity Reaction to High-Dose Methotrexate and Successful Rechallenge in a Pediatric Patient with Osteosarcoma

Jeffrey R. Scott, PharmD¹, Deborah A. Ward, PharmD¹, Kristine R. Crews, PharmD¹, John C. Panetta, PhD¹, and Fariba Navid, MD^{2,3}

¹Pharmaceutical Department, St. Jude Children's Research Hospital, Memphis, TN

²Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

³Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN

Abstract

Hypersensitivity reactions to methotrexate are rare, but have been reported. Methotrexate has shown activity against many malignancies, and omission of methotrexate therapy may increase the risk of cancer-related death in some patients. Therefore, rechallenging patients with methotrexate following hypersensitivity may be beneficial. We report a case of a child with metastatic osteosarcoma who experienced a hypersensitivity reaction to high-dose methotrexate and was successfully rechallenged with methotrexate using a 6-hour infusion. Using this regimen, adequate peak methotrexate plasma concentrations were achieved and no further hypersensitivity reactions were noted.

Keywords

methotrexate; pediatric; osteosarcoma; anaphylaxis; hypersensitivity

INTRODUCTION

Methotrexate is a dihydrofolate reductase inhibitor that is widely used in pediatric oncology for the treatment of both hematologic and non-hematologic malignancy. High-dose methotrexate with leucovorin rescue is commonly used for the treatment of osteosarcoma¹. The major side effects of high-dose methotrexate include mucositis, nephrotoxicity, hepatotoxicity, neurotoxicity, and pulmonary toxicity. Hypersensitivity reactions to high-dose methotrexate are uncommon, but have been reported^{2–14}. Rechallenging pediatric oncology patients with high-dose methotrexate following hypersensitivity reactions has also been reported in the literature^{4–6,10,13,14}. In osteosarcoma patients, these case reports have often used extended infusions (e.g., infusion times of up to 27 hours) to desensitize patients

Please send correspondence to: Jeffrey Scott, PharmD, BCPS, Clinical Pharmacy Specialist, Pharmaceutical Services Department, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mailstop 150, Memphis, TN 38105, Office: (901) 595-2977, Fax: (901) 595-3111, jeffrey.scott@stjude.org.

Conflicts of interest: The authors have no relevant conflicts of interest to disclose.

to methotrexate^{4,14}. Data suggest that attainment of adequate peak methotrexate plasma concentrations (700–1000 $\mu\text{mol/L}$) is important for successful outcomes in osteosarcoma patients^{15–18}. Therefore, extended infusions of high-dose methotrexate, which result in lower peak plasma concentrations, are not ideal for the treatment of osteosarcoma. We report a case of a hypersensitivity reaction to methotrexate in a child with metastatic osteosarcoma who was successfully rechallenged with high-dose methotrexate and attained adequate peak methotrexate plasma concentrations using a 6 hour infusion.

CASE REPORT

The patient is a 9 year old female diagnosed with osteosarcoma of the right humerus with metastases to the lungs and multiple bony sites treated on an institutional front-line osteosarcoma protocol (NCT00667342) to evaluate bevacizumab in combination with chemotherapy consisting of high-dose methotrexate, doxorubicin, cisplatin, ifosfamide and etoposide. High-dose methotrexate was administered at weeks 3, 4, 8, 9, 23, 24, 31, 32, 36 and 37. Her first course of high-dose methotrexate was complicated by delayed excretion and acute kidney injury requiring glucarpidase administration; however, no hypersensitivity reaction was noted. A summary of the pharmacokinetics for this and future high-dose methotrexate courses is depicted in Table 1. For her second course of high-dose methotrexate, the dosage was reduced from 12,000 mg/m^2 to 8,000 mg/m^2 based on her delayed excretion with course 1.¹⁹ During the course 2 high-dose methotrexate infusion, she developed respiratory distress, cough, rash, hives, pruritis, and facial and tongue swelling approximately 2.6 hours into the infusion. The patient's methotrexate infusion was stopped, and she was given IV diphenhydramine. At that time, the patient had received approximately 65% of the total dose (5213 mg/m^2). Symptoms rapidly improved following diphenhydramine administration; however, the infusion was not restarted. A methotrexate plasma concentration that was obtained 36 minutes after the infusion was discontinued was 579 $\mu\text{mol/L}$. She subsequently cleared her second course of methotrexate at hour 72 (i.e., methotrexate plasma concentration < 0.1 $\mu\text{mol/L}$) with no late toxicity noted (Figure 1).

Following this reaction, the decision was made to rechallenge the patient with high-dose methotrexate based on the extent of her disease and the potential benefit of methotrexate therapy. A plan for rechallenging the patient with methotrexate was developed using the estimated pharmacokinetics from the previous course, with goals of avoiding a hypersensitivity reaction while achieving an end-of-infusion methotrexate plasma concentration of 700–1000 $\mu\text{mol/L}$ so that efficacy could be maintained. The patient's MTX pharmacokinetics were estimated by fitting a first-order two-compartment pharmacokinetic model to the patient's high-dose methotrexate concentration-time data using the MAP estimation algorithm as implemented in ADAPTII (Biomedical Simulations Resource, University of Southern California, Los Angeles, CA) and the prior pharmacokinetic parameter distribution from previous OS studies¹⁶. Simulations indicated that adequate peak methotrexate plasma concentrations could be attained (700–1000 $\mu\text{mol/L}$)^{1,15–18} using a dosage of 8 g/m^2 given as a 6 hour infusion (Figure 1).

For high-dose methotrexate course 3, the patient was given premedication with dexamethasone 4mg PO q12h beginning 24hrs prior to admission. She was admitted

overnight for prehydration with D5W + 10 mEq/L KCl + 40 mEq/L NaHCO₃ at 200 mL/m²/hr and received the following immediately prior to initiation of methotrexate: hydrocortisone IV 50 mg/m², diphenhydramine IV 1 mg/kg, and ranitidine IV 1 mg/kg. Epinephrine, methylprednisolone, and diphenhydramine were available at the patient's bedside in case of anaphylaxis.

For course 3, methotrexate 8 g/m² infusion (dose rounded to 8.26 g/m²) was diluted in 1500 mL/m² (increased from the standard volume of 800 mL/m²) to a final concentration of 5.4 mg/mL. After premedication, 4% of the total dose was administered over the first hour of the infusion. At hour 1, the infusion rate was increased so that 8% total dose was given over the second hour of the infusion. At hour 2, the patient was redosed with hydrocortisone IV 50 mg/m² and the methotrexate infusion was increased to full rate (88% of the total dose over 4 hrs). At hour 4, the patient was redosed with diphenhydramine IV 1 mg/kg. Leucovorin rescue 15 mg/m² PO q6h x6 doses was initiated at hour 30 per institutional protocol. Hydration continued at 200 mL/m²/hr.

The patient tolerated the high-dose methotrexate course 3 well. Plasma methotrexate concentrations were measured by fluorescent polarization immunoassay (TDx System; Abbott Laboratories, Abbott Park, IL). Her peak methotrexate plasma concentration was 798 µmol/L after the extended 6 hour infusion and she cleared methotrexate at hour 96 with no notable toxicity. A rechallenge was also attempted with course 4 using the above approach. The patient's peak methotrexate plasma concentration for course 4 was 809.6 µmol/L. During this course, she cleared methotrexate at hour 120. The patient experienced grade II mucositis following course 4; however, the mucositis quickly resolved with increased leucovorin rescue and no additional complications were noted.

For courses 5 and 6, high-dose methotrexate was infused over 4 hours. For course 5, she was given 8 g/m², and the dosage for course 6 was increased to 10 g/m². Premedications were given in courses 5 and 6 as with courses 3 and 4. The patient tolerated these courses well, with peak levels of 809.4 and 842.4 µmol/L, respectively. She cleared courses 5 and 6 methotrexate at hour 72 with no toxicity noted. The patient was subsequently taken off of protocol due to progressive disease.

DISCUSSION

Methotrexate hypersensitivity reactions, although rare, present a challenge for clinicians. Although further high-dose methotrexate therapy may be omitted from chemotherapy regimens in some cases, this omission may increase a patient's risk for cancer-related death¹. Therefore, a rechallenge with high-dose methotrexate should be considered. Previous reports of methotrexate rechallenge in osteosarcoma have used extended infusions up to 27 hours for desensitization.^{4,14} Although these rechallenges have been successful in some cases, there is question whether the efficacy of high-dose methotrexate is decreased by the use of extended infusions.^{1,15–18} Furthermore, a significantly extended high-dose methotrexate infusion may increase a patient's risk for methotrexate toxicity.^{4,20} Therefore, a shorter infusion is desirable in osteosarcoma patients to maximize efficacy and decrease toxicity of methotrexate. This case report illustrates how an individual patient's available

methotrexate pharmacokinetic data was used to select a dosage and an infusion rate that would attain adequate peak plasma concentrations when rechallenging a patient with a prior hypersensitivity reaction. We showed that, based on the pharmacokinetic modeling for our patient, using a 6 hour high-dose methotrexate infusion was feasible, and adequate peak methotrexate plasma concentrations were obtained.

Acknowledgments

Supported by NIH CA-21765 and the American Lebanese Syrian Associated Charities (ALSAC)

References

1. Jaffe N, Gorlick R. High-dose methotrexate in osteosarcoma: let the questions surcease--time for final acceptance. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Sep 20; 2008 26(27):4365–4366. [PubMed: 18802144]
2. Alkins SA, Byrd JC, Morgan SK, Ward FT, Weiss RB. Anaphylactoid reactions to methotrexate. *Cancer*. May 15; 1996 77(10):2123–2126. [PubMed: 8640680]
3. al-Lamki Z, Thomas E, el-Banna N, Jaffe N. Acute urticaria and hepatitis complicating high-dose methotrexate therapy. *Medical and pediatric oncology*. Feb; 1995 24(2):137–140. [PubMed: 7990763]
4. Bouchireb K, Dodille A, Ponvert C, Gouraud F, Dubrel M, Brugieres L. Management and successful desensitization in methotrexate-induced anaphylaxis. *Pediatric blood & cancer*. Feb; 2009 52(2):295–297. [PubMed: 18855892]
5. Caldeira T, Costa V, Silva I, Oliva T, Norton L. Anaphylactoid reaction to high-dose methotrexate and re-administration after a successful desensitization. *Pediatric hematology and oncology*. Mar; 2008 25(2):131–134. [PubMed: 18363180]
6. Davis KA, Williams P, Walker JC. Successful desensitization to high-dose methotrexate after systemic anaphylaxis. *Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology*. Jan; 2003 90(1):87–89.
7. Elkiran ET, Altundag K, Aksoy S, Onal IK, Tekuzman G. Systemic anaphylactic reaction following intrathecal administration of methotrexate in adult patient with primary central nervous system lymphoma. *American journal of hematology*. Apr.2004 75(4):265. [PubMed: 15054831]
8. Gluck-Kuyt I, Irwin LE. Anaphylactic reaction to high-dose methotrexate. *Cancer treatment reports*. May; 1979 63(5):797–798. [PubMed: 455318]
9. Goldberg NH, Romolo JL, Austin EH, Drake J, Rosenberg SA. Anaphylactoid type reactions in two patients receiving high dose intravenous methotrexate. *Cancer*. Jan; 1978 41(1):52–55. [PubMed: 272226]
10. Kohli A, Ferencz TM, Calderon JG. Readministration of high-dose methotrexate in a patient with suspected immediate hypersensitivity and T-cell acute lymphoblastic lymphoma. *Allergy and asthma proceedings: the official journal of regional and state allergy societies*. Jul-Aug;2004 25(4):249–252. [PubMed: 15510585]
11. Lluch-Bernal M, Cuesta-Herranz J, De las Heras M, et al. Anaphylactic reaction to methotrexate. *Allergy*. Nov; 1997 52(11):1150–1151. [PubMed: 9404577]
12. Lobelle C, Lopez Rivas M, Barreiro J, Rodicio M, Couselo JM. Anaphylactic reaction to high-dose methotrexate. *Pediatric hematology and oncology*. Mar-Apr;1995 12(2):213–214. [PubMed: 7626394]
13. MacGinnitie AJ, Walensky LD, Turvey SE, et al. Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge. *Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology*. Oct; 2003 14(5):409–411. [PubMed: 14641613]
14. Oulego-Eroz I, Maneiro-Freire M, Bouzon-Alejandro M, Vazquez-Donsion M, Couselo JM. Anaphylactoid reaction to high-dose methotrexate and successful desensitization. *Pediatric blood & cancer*. Sep; 2010 55(3):557–559. [PubMed: 20533520]

15. Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Feb; 1998 16(2):658–663. [PubMed: 9469355]
16. Crews KR, Liu T, Rodriguez-Galindo C, et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. *Cancer*. Apr 15; 2004 100(8):1724–1733. [PubMed: 15073863]
17. Delepine N, Delepine G, Jasmin C, Desbois JC, Cornille H, Mathe G. Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 1988; 42(4):257–262. [PubMed: 3191203]
18. Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Jul; 1994 12(7):1443–1451. [PubMed: 8021736]
19. Christensen AM, Pauley JL, Molinelli AR, et al. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. *Cancer*. Sep 1; 2012 118(17):4321–4330. [PubMed: 22252903]
20. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. *Blood*. Feb 1; 2005 105(3):948–958. [PubMed: 15486066]

Figure 1.

Pharmacokinetic simulations of courses 2 and 3 high-dose methotrexate

The solid line and squares are the plasma methotrexate plasma concentration data and fitted curve for course 2 high-dose methotrexate (5.2g/m^2 over approximately 2.6 hours). The dashed line is the simulated course 3 curve (8g/m^2 over 6 hours) based on course 2 pharmacokinetics. The dotted line and stars are the actual course 3 fitted curve and data.

Table 1

Methotrexate pharmacokinetic profiles for courses 1–6 with model estimates

MTX course	MTX dose (g/m ²)	Infusion time (hr)	Methotrexate Plasma Concentrations (uM)				Cl (mL/min/m ²)	AUC (uM hr) [*]	Cmax (uM) [*]
			Time						
			Peak	24 hr	48 hr	72 hr			
1	12	4	1627	61	0.75	0.62	30.99	13637	1651
2	5.2	2.6	578.6	2.9	0.25	0.08	52.59	3632	673.7
3	8	6	797.6	2.1	0.46	0.14	65.23	4640	814.1
4	8	6	809.6	3.6	0.35	0.13	59.67	5024	827.4
5	8	4	809.4	1.1	0.12	0.03	62.69	4499	862.4
6	10	4	842.4	1.7	0.15	0.04	79.43	4775	869.1

^{*} calculations based on pharmacokinetic model estimations
MTX, methotrexate; Cl, clearance; AUC, area under the methotrexate plasma concentration-time curve; Cmax, peak methotrexate plasma concentration.